(TheNewswire)
Toronto, Ontario / TheNewswire / July 17,
2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce
that the Mazankowski Alberta Heart Institute in Edmonton, Alberta has begun
a study to evaluate the ability of the Ventripoint VMS+ heart analysis system to analyze poor quality images, where contrast
enhanced 2D echocardiography would normally be performed to get better images.
“We are very pleased to have such a high profile cardiac institution using our system to improve patient care
and outcomes,” commented Desmond Hirson, President of Ventripoint.
In 10-20% of patients the images collected by standard 2D ultrasound are not clear enough to allow
for interpretation using conventional methods. Using the artificial intelligence (AI) approach embedded in the VMS+ heart analysis
system, the standard images can be analyzed. Normally in these patients, a second exam is immediately performed using the
injection of a contrast media, which enhances the ability to see the heart walls and allows for conventional analysis in most
cases.
The reduction in the number of contrast-enhanced 2D echo studies would represent a significant
savings in time and costs for echocardiology departments. It would also reduce the need to inject the patient with contrast
media. The use of contrast-enhanced ultrasound is increasing in the western world with the burgeoning population of heavier people
making it more difficult to obtain clear images using ultrasound.
The clinical study is expected to take about three months and include 40-50 patients.
About Mazankowski Alberta Heart Institute
The Mazankowski Alberta Heart Institute in Edmonton is a world leader in
complex cardiac care and surgery. With a collaborative approach, its team of highly skilled cardiologists, cardiovascular surgeons,
cardiac care professionals, researchers and educators is advancing the prevention, detection, treatment and study of cardiovascular
disease.
In other news, on June 22, 2018 the Board of Directors granted a total of 325,000 common share stock options to
three officers and 300,000 stock options to four independent directors of the Company. All options are exercisable at $0.31 per
share until the fifth anniversary date of the grant.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information, please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.